Retinitis pigmentosa (tapetoretinal degeneration or retinal abiotrophy) is a disease whose aetiology
is not yet known. Retinal degeneration occurs secondarily in such disorders like abetalipoproteinaemia, Refsum's disease, and others. Rocha and Antunes' suggested that primary retinitis pigmentosa may be an autoimmune disease. Gouras and Chader2 proposed a possible role for retinol binding protein in retinitis pigmentosa. Gahlot et al.3 suggested that the primary defect in retinitis pigmentosa is in copper metabolism. They reported decreased serum ceruloplasmin and increased urinary copper excretion in every patient they examined.34 Investigators in the United States5 and Denmark6 who have conducted similar studies of copper metabolism on retinitis pigmentosa patients found no abnormalities in copper metabolism similar to those found by Gahlot et al. Discussing their results, Marmor et al. 5 considered it possible that Gahlot et al. from India were studying a genetic isolate of retinitis pigmentosa patients in whom copper metabolism is altered. We considered it worth while to investigate copper metabolism in retinitis pigmentosa patients, and we report here that about a third of all patients we investigated showed abnormalities of copper metabolism of the nature described by Gahlot et al. diagnosed as suffering from primary retinitis pigmentosa was included in this study. They were all informed of the nature of the study. The normal subjects were the surgeons at Sarojini Devi Eye Hospital and the staff of the Institute of Genetics and their family members.
After the diagnosis had been made and it was established that the patients suffered from no other disease the following 3 parameters were measured on these patients: (1) serum copper was measured by the method of Giorgio et al.7; (2) ceruloplasmin concentration in serum was measured from the rate of oxidation of p-phenylenediamine as described by Henry et al.8; (3) copper content in 24 h urine samples was measured by the method of Giorgio et al. 7 The same parameters were measured in normal subjects by the same methods.
Results
Serum copper and ceruloplasmin concentrations and urinary excretion of copper for 13 normal subjects are shown in (Table 3 ). This value is close to the report of Gahlot. Also, when these 8 are excluded from the rest of the patients, the urinary excretion for these patients averaged 40-0 ,g and is comparable with that for control subjects. The 8 patients with increased urinary copper excretion and the rest of the patients had comparable ceruloplasmin concentrations (Table 3 ). The serum copper was raised in the rest of the patients but not to the same level as in the 8 patients with increased urinary copper excretion (Table 3) . The dietary copper is absorbed from the intestine and transported to the liver mainly bound to albumin. There copper is incorporated into ceruloplasmin and released into the blood stream. The ceruloplasmin-bound copper represents about 90% of the total serum copper. Urinary excretion of copper is minimal, while the major mode of excretion is through faeces. However, in Wilson's disease, where copper accumulates in tissues, the ceruloplasmin content of serum drops to below 10 mg per 100 ml in about 80% of the patients, and the urinary copper excretion is often as high as 1000 ,tg or more per day.'1 Wilson's disease is treated with decoppering agents like D-penicillamine. Gahlot4 reported treatment of retinitis pigmentosa patients with a decoppering agent and low copper diet and suggested that both acuity and fields of vision improved after a few months of treatment. We feel that the decrease in ceruloplasmin concentration and the rise in urinary copper in the 8 patients we isolated are not comparable in severity to those of Wilson's disease to warrant treatment with decoppering agents. We are advising low copper diet therapy to these 8 patients to see if that alone brings about the desired improvements.
